Enterprise

RingCentral's Paid AI Products Now Reach 13% of Revenue Base

The communications platform doubled its AI customer footprint year-over-year, but modest overall growth leaves investors weighing execution risk.

Omega Editorial· September 5, 2026· 3 min read

RingCentral has put a number on its artificial intelligence momentum: customers using at least one paid native AI product now account for approximately 13% of the company's annual recurring revenue, according to figures the communications platform disclosed on July 23. That metric has doubled from the year-earlier period, giving the vendor's AI strategy a concrete commercial benchmark as shares trade near four-year highs following a 141% climb over the preceding twelve months.

Second-quarter performance shows profitability gains

The company's second-quarter results showed revenue climbing 5.9% to $657 million, with subscription revenue up 5.8% to $634 million. GAAP operating margin reached 7.7%. Management responded by raising full-year revenue guidance, lifting free-cash-flow projections to a range of $615 million to $625 million, and increasing the dividend by 67%. The details were first reported by AI Watch.

The 13% ARR figure describes the recurring revenue tied to customers who have adopted a paid AI product—not standalone AI revenue or proof that artificial intelligence drove every dollar within that cohort. The distinction carries weight when investors attempt to model AI-driven expansion and assign valuation multiples to growth.

Why it matters

RingCentral's disclosure offers one of the clearer early reads on how enterprise AI adoption translates into measurable commercial traction for a communications software vendor. The doubling of AI-linked ARR demonstrates that paid products are gaining real customer uptake beyond pilot programs. Yet the company's headline growth remains in the mid-single digits, and the stock's sharp rebound means much of the profitability improvement is already reflected in the price. For investors, the central question is whether AI can accelerate total company growth while margins expand—or whether adoption will deepen spending within a revenue pool that expands too slowly to justify current valuations.

Competitive pressure and investor positioning

Communications software remains a contested market. Microsoft, Zoom, contact-center specialists, and newer AI-native services all compete for enterprise budgets, and switching costs are not absolute. Pricing pressure can limit how much AI features translate into durable revenue gains.

Hedge fund interest ticked modestly higher during the second quarter, with 27 funds holding positions as of June 30, up from 25 in the first quarter. AQR Capital Management reported 1,537,795 shares. Short interest stood at 7.06 million shares, or 9.12% of float, as of the August 14 settlement date—down 7.7% from 7.65 million shares on July 31, with 3.8 days to cover.

The path forward hinges on whether net retention, seat growth, and free cash flow move in tandem with the rising share of customers using paid AI products. A higher AI-usage percentage alone could mask stagnation in the broader revenue base, leaving long-term shareholders with limited upside in a market that has already priced in much of the turnaround.

The figures and analysis were originally reported by AI Watch.

#ringcentral#enterprise ai#communications software#annual recurring revenue#ai monetization#saas

This is an original analysis by the Omega editorial team. Source reporting: AI Watch.

Want systems like this working for your business?

Book a Call

More in Enterprise

Enterprise· 4 min read

Dr. Martens Rebuilt Customer Service From Scratch After Years of Decline

The footwear brand consolidated fragmented systems across regions onto Salesforce and AWS, reversing a three-year slide in customer satisfaction within months.

Via Automation Watch · Sep 24, 2026
Enterprise· 4 min read

AI Coding Tools Added $942M to Hospital Bills Without Care Changes

Blue Cross Blue Shield Association analysis finds hospitals using automation to classify more cases as complex, driving up costs with no documented increase in treatment intensity.

Via AI Watch · Sep 24, 2026
Enterprise· 4 min read

AI Clinical Trial Endpoints Fail at Scale Without Data Harmonization

Analysis of over one million patient screenings reveals that AI validation in single sites masks critical performance drift across multi-site deployments.

Via AI Watch · Sep 24, 2026